<DOC>
	<DOCNO>NCT01658722</DOCNO>
	<brief_summary>A Phase 3b , Study Subjects With Alzheimer 's Disease Who Discontinued Treatment Bapineuzumab Phase 3 Clinical Studies ( ELN115727-301/302/351 ) Who Completed Studies ELN115727-301 302 Enroll Study ELN115727-351 .</brief_summary>
	<brief_title>Retrieval Patient Information After Discontinuation</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Signed , date , write informed consent obtain subject and/or subject 's legally acceptable representative ( LAR , applicable ) accordance local regulation . 2 . Signed , date , write informed consent , obtain subject 's caregiver accordance local regulation . 3 . Subject must participate Study 301 , 302 , 351 receive least 1 dose study treatment ( bapineuzumab placebo ) . 4 . Subject must treatment least 12 month prior Visit 1 . 5 . Subjects must primary caregiver duration study . 6 . Subject 's caregiver must ability ass subject answer question phone .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>